Search results
Jun 27, 2024 · Escape from T-cell–targeting immunotherapies in acute myeloid leukemia. Jayakumar Vadakekolathu, Sergio Rutella. Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML).
- First Edition
Eltrombopag plus diacerein vs. eltrombopag in patients with...
- First Edition
Jun 20, 2024 · Read the latest articles of Blood at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature.
1 day ago · Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial. Lu Sun, Xiaoyang Huang, Juan Wang, Chenglu Yuan, Hongyu Zhao, Daqi Li, Ruirong Xu, Yan Wang, Pin Qin, Yan Shi, Jun Peng, Ming Hou, Yu Hou. View article.
2 days ago · Zhang Y, Moschetta M, Huynh D, et al. Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014;124 (17):2675-2686. Page 124. View PDF. Read the latest articles of Blood at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature.
Jun 27, 2024 · Read the latest articles of Blood at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature.
Jun 20, 2024 · Key Points. The CLL-IPI retains prognostic value for PFS, but its impact appears diminished in predicting survival with targeted drugs. Improved survival with targeted therapies vs chemoimmunotherapy underscores the need to reevaluate prognostic tools amid treatment shifts.
Jun 25, 2024 · Prognostic measures to identify those at greatest risk for thrombosis, progression, and death in ET (events) are important for timely risk-adapted intervention with available treatments, and for ...
